A Study to Assess the Change in Disease State in Adult Participants Being Treated With Oral Upadacitinib Tablets in Participants With Oligo- or Poly-artIcular Psoriatic Arthritis
UPJOINT
Real-World Effectiveness of Upadacitinib in Patients Joining Subgroups Either With Oligo- or Poly-ArtIcular Psoriatic Arthritis on Minimal Disease Activity
1 other identifier
observational
394
2 countries
93
Brief Summary
Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis. It is caused by the body's immune system mistakenly attacking healthy joint tissue causing inflammation, joint damage, disability, and a reduced life expectancy. The main objective of this study is to characterize attainment of minimal disease activity (MDA) at week 24 under continuous treatment with upadacitinib in participants with oligo- or polyarticular PsA as part of real-world practice. Upadacitinib is a drug approved for the treatment of Psoriatic arthritis (PsA) in Germany and Canada. Approximately 380 adult participants with PsA at multiple sites in Germany and Canada. Participants will receive oral Upadacitinib tablets per current local label, according to local standard of care and international guidelines. There may be a higher burden for participants in this study compared to standard of care. Participants will attend regular visits per routine clinical practice. The effect of the treatment will be checked by medical assessments, checking for side effects, and by questionnaire.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2021
Typical duration for all trials
93 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 4, 2021
CompletedFirst Submitted
Initial submission to the registry
February 16, 2021
CompletedFirst Posted
Study publicly available on registry
February 17, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 26, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
July 26, 2023
CompletedJuly 17, 2024
July 1, 2024
2.5 years
February 16, 2021
July 16, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Percentage of Participants Receiving Upadacitinib who Attain Minimal Disease Activity (MDA)
MDA will be determined based on participants fulfilling 5 of 7 outcome measures: tender joint count 68 (TJC68) \<= 1, swollen joint count (SJC66) ≤ 1, body surface area (BSA) \<= 3%; Patient's Assessment of Pain numeric rating scale (NRS) \<= 1.5, Patient's Global Assessment of Disease Activity (PtGA) NRS \<= 2.0, Health Assessment Questionnaire Disability Index (HAQ-DI) \<= 0.5, tender entheseal points \<= 1.
At Week 24
Secondary Outcomes (7)
Percentage of Participants Maintaining MDA Under Upadacitinib Treatment, in Participants who had Achieved MDA at Week 24
At Week 48
Mean change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Question 2 (Pain in Neck, Back or Hip)
Baseline to Week 48
Mean Change in Disease Activity in PSoriatic Arthritis score (DAPSA)
Baseline to Week 48
Mean Change in Percentage of Participants with Dactylitis
Baseline to Week 48
Mean Change in Number of Fingernails Affected with Psoriasis
Baseline to Week 48
- +2 more secondary outcomes
Study Arms (1)
Participants Receiving Upadacitinib
Participants receiving Upadacitinib for psoriatic arthritis (PsA).
Eligibility Criteria
Participants with psoriatic arthritis (PsA).
You may qualify if:
- Diagnosis of active Psoriatic Arthritis (PsA) upon judgment of the treating physician.
- Swollen joint count (SJC) \>= 1 out of 66 joints.
- Decision on the treatment with Upadacitinib was made prior to any decision to approach the participant to participate in this study.
You may not qualify if:
- Cannot be treated with Upadacitinib according to the local Upadacitinib Summary of Product Characteristics (SmPC).
- Prior treatment with Upadacitinib.
- Currently participating in interventional research or within the last 30 days.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AbbVielead
Study Sites (93)
Dr. Jonathan D. Chan Inc. /ID# 241611
Vancouver, British Columbia, V5Z 1J9, Canada
Manitoba Clinic /ID# 234148
Winnipeg, Manitoba, R3A 1M3, Canada
The Waterside Clinic /ID# 234146
Barrie, Ontario, L4M 6L2, Canada
Dr. Chrisostomos Kouroukis & Dr. Pauline Boulos MPC /ID# 233565
Dundas, Ontario, L9H 1B7, Canada
Arthur Karasik Medicine Professional Corporation /ID# 234147
Etobicoke, Ontario, M9C 5N2, Canada
Lau Bacchus Professional Medicine Corp /ID# 245283
Hamilton, Ontario, L8N 1Y2, Canada
Credit Valley Rheumatology /ID# 234144
Mississauga, Ontario, L5M 2V8, Canada
Dr. L. Lisnevskaia Medicine Professional Corporation /ID# 239611
Oshawa, Ontario, L1H 1B9, Canada
Angela Montgomery Medicine Professional Corporation /ID# 239608
Ottawa, Ontario, K1H 7X3, Canada
Niagara Peninsula Arthritis Ct /ID# 245521
St. Catharines, Ontario, L2N 7E4, Canada
Dr. Sabeen Anwar Medicine Professional Corporation /ID# 242696
Windsor, Ontario, N8X 1T3, Canada
Applied Medical Informatics Research Inc. (AMIR) /ID# 239614
Montreal, Quebec, H4A 3T2, Canada
Clinique de Rhumatologie de Montreal /ID# 239613
Montreal, Quebec, H4N 1C6, Canada
CISSSBSL -Hopital regional de Rimouski /ID# 234150
Rimouski, Quebec, G5L 5T1, Canada
Groupe de Recherche en Maladies Osseuses Inc /ID# 234145
Sainte-Foy, Quebec, G1V 3M7, Canada
CIUSSS de l'Estrie - CHUS /ID# 241054
Sherbrooke, Quebec, J1G 2E8, Canada
Centre de Recherche Musculo-Squelettique /ID# 234151
Trois-Rivières, Quebec, G8Z 1Y2, Canada
Dr Naik-Medical Professional Corporation-Alliance Health /ID# 234149
Saskatoon, Saskatchewan, S7H 5M7, Canada
Praxis Dr. Rinaldi /ID# 228639
Ulm, Baden-Wurttemberg, 89073, Germany
Praxis Dres. Kellerer/Kellerer/Krüger /ID# 227414
Munich, Bavaria, 81541, Germany
Rheumahaus Studien GbR, Potsdam, DE /ID# 230771
Potsdam, Brandenburg, 14467, Germany
Internistisches Praxiszentrum /ID# 228262
Giessen, Hesse, 35392, Germany
Fachpraxis fuer Rheumatologie und Osteologie /ID# 227391
Bruchhausen-Vilsen, Lower Saxony, 27305, Germany
Kupka & Kupka, Altenburg, DE /ID# 228243
Altenburg, 04600, Germany
Marycz, Amberg, DE /ID# 227413
Amberg, 92224, Germany
Rheumapraxis am Webereck /ID# 229274
Augsburg, 86157, Germany
MVZ Weserbergland /ID# 228806
Bad Pyrmont, 31812, Germany
ACURA Rheumazentrum Baden-Bade /ID# 239202
Baden-Baden, 76530, Germany
Rheumapraxis Prof Dr Karin Manger /ID# 229120
Bamberg, 96047, Germany
Sozialstiftung Bamberg /ID# 228549
Bamberg, 96049, Germany
Internistische-rheumatologische Praxisgemeinschaft /ID# 228240
Bayreuth, 95444, Germany
MVZ Rheumatologie /ID# 240868
Berlin, 10117, Germany
Praxis Dr. med. Angela Seifert /ID# 233772
Berlin, 12555, Germany
Praxis Dr. Silke Zinke /ID# 229127
Berlin, 13055, Germany
Rheumapraxis am Schlachtensee /ID# 228800
Berlin, 14129, Germany
Eisterhues, Braunschweig, DE /ID# 227390
Braunschweig, 38100, Germany
Dres. Schuh /ID# 227411
Coburg, 96450, Germany
Rheumatologie in Veedel /ID# 228469
Cologne, 50825, Germany
Krankenhaus Porz am Rhein /ID# 228358
Cologne, 51149, Germany
Praxis Dr. Kirrstetter /ID# 229609
Deggendorf, 94469, Germany
Kreiskrankenhaus Demmin /ID# 228253
Demmin, 17109, Germany
Rheumatologisches MVZ Dresden /ID# 230787
Dresden, 01109, Germany
Praxis Dilltal /ID# 228640
Ehringshausen, 35630, Germany
MVZ Ambulantes Rheumazentrum Erfurt /ID# 248933
Erfurt, 99096, Germany
Dres. Waehrisch/Flaxenberg /ID# 228263
Essen, 45326, Germany
Michael Mueller, Freiberg, DE /ID# 228468
Freiberg, 09599, Germany
Praxis Dr. Behringer /ID# 229275
Fulda, 36039, Germany
Rockwitz, Goslar, DE /ID# 227856
Goslar, 38642, Germany
Praxis Fiene /ID# 244732
Greifswald, 17493, Germany
Praxis Dr. Kuehne /ID# 229119
Haldensleben I, 39340, Germany
Praxis Dr. Liebhaber /ID# 228636
Halle, 06128, Germany
Stille, Hanover, DE /ID# 229604
Hanover, 30161, Germany
Heilig, Heidelberg, DE /ID# 228356
Heidelberg, 69120, Germany
St. Elisabeth Gruppe GmbH -Katholische Kliniken /ID# 228797
Herne, 44649, Germany
Praxis Bernd Mueller /ID# 230776
Homburg, 66424, Germany
Praxis K. Pagel /ID# 228247
Hoppegarten, 15366, Germany
Kremers, Juelich, DE /ID# 240383
Jülich, 52428, Germany
Rheumapraxis Kaufering /ID# 231391
Kaufering, 86916, Germany
Alb-Donau Klinikum, Langenau /ID# 233770
Langenau, 89129, Germany
Hamann & Teich & Boche,Leipzig /ID# 228355
Leipzig, 04109, Germany
Praxis internistische Rheumatologie /ID# 227857
Leipzig, 04129, Germany
Dres. Teipel/Toussaint/Saech /ID# 228465
Leverkusen, 51373, Germany
Dr. Bolze, Ludwigshafen, DE /ID# 230773
Ludwigshafen, 67069, Germany
Aurich & Sieburg, Magdeburg /ID# 229605
Magdeburg, 39104, Germany
Praxis Dr. Annekatrin Rossbach /ID# 230783
Mansfeld / Großörner, 06343, Germany
Harmuth, Marktredwitz, DE /ID# 227709
Marktredwitz, 95615, Germany
RHIO Forschungsinstitut /ID# 227736
Meerbusch, 40668, Germany
Vollmer & Partner, DE /ID# 240869
Mönchengladbach, 41061, Germany
Prof-med-stud.de /ID# 228637
Munich, 80935, Germany
Rheumatologische Facharztpraxis /ID# 228808
Naumburg, 06618, Germany
Berger, Naunhof, DE /ID# 229612
Naunhof, 04683, Germany
Praxis Dr. med Thilo Klopsch /ID# 229123
Neubrandenburg, 17033, Germany
Erbsloeh-Moeller, Neunkirchen /ID# 230778
Neunkirchen, 66538, Germany
MVZ Medic-Center Nürnberg GmbH /ID# 240982
Nuremberg, 90443, Germany
Die Fachaerzte im Rottal - Nephrologie, Rheumatologie /ID# 230774
Pfarrkirchen, 84347, Germany
MVZ für Rheumatologie Dr. M. Welcker /ID# 227858
Planegg, 82152, Germany
Baumann & Lang, Plauen, DE /ID# 229128
Plauen, 08523, Germany
Praxis Dr. Sabine Reckert /ID# 248986
Potsdam, 14469, Germany
Knappschaftsklinikum Saar /ID# 248882
Püttlingen, 66346, Germany
Rheumazentrum Ratingen /ID# 228261
Ratingen, 40882, Germany
Rheumatologische Praxis Dr. Jochen Walter /ID# 229607
Rendsburg, 24768, Germany
Rheumatologische Gemeinschaftspraxis Schwerin /ID# 228260
Schwerin, 19053, Germany
Melzer, Seesen, DE /ID# 227386
Seesen, 38723, Germany
Barmherzige Bruder MVZ Klinikum Straubing GmbH /ID# 228805
Straubing, 94315, Germany
Krankenhaus der Barmherzigen Brueder Trier /ID# 229603
Trier, 54292, Germany
Praxis Dr. Haas /ID# 228813
Tübingen, 72072, Germany
Rheumathologie Ulm /ID# 238801
Ulm, 89073, Germany
MVZ Lahn-Dill-Kliniken GmbH /ID# 231390
Wetzlar, 35578, Germany
MVZ Lahn-Dill-Kliniken GmbH /ID# 262011
Wetzlar, 35578, Germany
Krankenhaus St. Josef /ID# 229611
Wuppertal, 42105, Germany
Praxis Barmen /ID# 227392
Wuppertal, 42285, Germany
Sprekeler, Zeven, DE /ID# 233773
Zeven, 27404, Germany
Fricke-Wagner, Zwickau, DE /ID# 230775
Zwickau, 08060, Germany
Related Publications (2)
Werner SG, Schwarze I, Baraliakos X, Fiene M, Walter J, Girard T, Laliberte MC, Jeromin K, Baschuk N, Allard-Charmard H, Bessette L, Hueber AJ. Effectiveness and Safety of Upadacitinib in Treating Oligoarticular and Polyarticular Psoriatic Arthritis: Primary Analysis from the UPJOINT-Study. Rheumatol Ther. 2026 Feb;13(1):45-64. doi: 10.1007/s40744-025-00802-5. Epub 2025 Nov 5.
PMID: 41191276DERIVEDWerner SG, Baraliakos X, Reckert S, Bohl-Buhler M, Laliberte MC, Girard T, Jeromin K, Baschuk N, Fritz B, Bessette L, Hueber AJ. Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice. Rheumatol Ther. 2023 Dec;10(6):1503-1518. doi: 10.1007/s40744-023-00589-3. Epub 2023 Sep 11.
PMID: 37695506DERIVED
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
ABBVIE INC.
AbbVie
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 16, 2021
First Posted
February 17, 2021
Study Start
February 4, 2021
Primary Completion
July 26, 2023
Study Completion
July 26, 2023
Last Updated
July 17, 2024
Record last verified: 2024-07